Opdivo/Yervoy Combination Fares Well in Lung Cancer Immunotherapy Trial – P&T Community
|
Opdivo/Yervoy Combination Fares Well in Lung Cancer Immunotherapy Trial
P&T Community Positive results have been reported from a crucial immunotherapy trial that used a combination of two Bristol-Myers Squibb (BMS) drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), to treat patients with a specific type of non–small-cell lung cancer … |
